Neuronetics (NASDAQ: STIM) — Company Overview, News & Financial Data
Neuronetics develops therapies for psychiatric disorders, focusing on transcranial magnetic stimulation for depression.
Neuronetics
Neuronetics (NASDAQ:STIM) is a medical technology company focused on developing innovative therapies for psychiatric and neurological disorders, with a particular emphasis on major depressive disorder. Their cornerstone project revolves around the NeuroStar Advanced Therapy system, a non-invasive treatment which utilizes transcranial magnetic stimulation (TMS) to target key areas of the brain associated with mood regulation. This technology offers hope to patients who haven't responded well to traditional antidepressant medications. With a mission to transform lives by offering new avenues in neurohealth, Neuronetics is dedicated to advancing their research and making their treatments more accessible to those in need. Their objectives include expanding the clinical applications of their technology, increasing adoption by healthcare providers, and continuing to build evidence for the efficacy and safety of their treatments.
Snapshot
Operations
Products and/or services of Neuronetics
- NeuroStar Advanced Therapy System, a non-invasive treatment for depression using transcranial magnetic stimulation.
- TouchStar treatment protocol, designed for shorter and more efficient sessions for patients undergoing depression therapy.
- NeuroStar Practice Consultants offer practices expertise in integrating NeuroStar therapy into clinical settings.
- NeuroStar Reimbursement Support Service assists patients and providers with insurance and reimbursement issues for treatments.
- MyNeuroStar.com provides resources for patients and clinicians, including educational materials and treatment tracking tools.
- NeuroStar Connect, a cloud-based platform that facilitates remote monitoring and management of treatment sessions by clinicians.
Neuronetics executive team
- Daniel L. ReuversCEO, President & Director
- Nir NaorExecutive VP, CFO, Corporate Secretary, Principal Financial and Accounting Officer & Treasurer
- Robert GreeneSenior Vice President of Sales
- Cory S. AndersonExecutive Vice President & General Manager of Greenbrook
Latest news about Neuronetics
Key financials
Reported results for Neuronetics, in USD.
- Market cap
- 172.2M
- Revenue (TTM)
- 155.1M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.4
- Dividend yield
- —
- Profit margin
- -19.6%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 149.2M | -31.4M | -39M | |
| 74.9M | -34.6M | -43.7M | |
| 71.3M | -30.6M | -30.2M | |
| 65.2M | -35.1M | -37.2M |